Study of MK0677 for the Treatment of Alzheimer's Disease

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: December 15, 2003
Last updated: January 30, 2009
Last verified: January 2009

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Condition Intervention Phase
Alzheimer's Disease
Drug: MK0677
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Cognitive function over 12 month period; safety and tolerability [ Time Frame: over 12 month period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog. [ Time Frame: over a 6 month and 12 month period ] [ Designated as safety issue: No ]

Enrollment: 512
Study Start Date: November 2003
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • Patients must have probable Alzheimer's disease of mild or moderate severity.
  • A brain scan and laboratory results must be consistent with Alzheimer's disease.
  • The patient must be otherwise medically healthy.
  Contacts and Locations
Please refer to this study by its identifier: NCT00074529

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc. Identifier: NCT00074529     History of Changes
Other Study ID Numbers: 2006_412, Formally-BG0812AZ, MK0677-030
Study First Received: December 15, 2003
Last Updated: January 30, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders processed this record on April 17, 2014